… T cells (Teffs) without inducing regulatory T cells (Tregs) in the tumor microenvironment;
conversely, IL-2 … High-dose IL-2 is approved for melanoma and renal cell carcinoma, but its …

… T cell growth factor activity of IL-2 resulted in this cytokine becoming the first immunotherapy
… -dose IL-2 as a first-line immunotherapy for metastatic renal cell carcinoma and melanoma. …

… T cell immunotherapy for melanoma, they administered orthoIL-2 to mice that received
infusions of transgenic T cells that recognize a peptide expressed by the melanoma cells. Prior to …

… This article reviews the latter type of engineering strategy. In addition, some researchers have
… Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl …

… of these cells after expansion in IL-2 have extended effective cell transfer therapy to other …
, efforts have turned to the genetic engineering of lymphocytes to express receptors capable of …

… natural killer (NK) cell growth factor IL-2 has been a sentinel force ushering in the era of
immunotherapy in cancer. With the advent of clinical grade recombinant IL-2 in the mid-1980s, …

… role of endogenous IL-2 for ICB responsiveness and the correlation between insufficient IL-2
signalling and T-cell exhaustion as tumours progress. To determine if exogenous IL-2 in the …

… expressed on cytotoxic T cells and natural killer (NK) cells, while trimeric … T cells for cancer
therapy, many engineering efforts have been focused on altering the binding affinity of IL-2 …

… ) cells have shown good application prospects in adoptive cellular immunotherapy against …
low activity, the therapeutic effect of infused NK cells has been limited in solid tumors, such as …

… the antitumor response at a cellular level, and … IL-2 in T cell biology and immunotherapy
IL-2 is a key signaling glycoprotein produced by antigen-activated T cells, which promotes T cell …